All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...

U.S. stock futures are pointing higher ahead of a closely watched inflation report; JPMorgan Chase shares are moving higher ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Asian shares are mixed after gains for oil and gas producers helped offset drops for Nvidia and other Big Tech companies on ...

The Dow Jones Industrial Average has been considered a reliable snapshot reference for the health of American industry for over 130 years. For those with only a cursory knowledge of American ...

A look at the top-yielding Dow Jones Industrial Average stocks. Changes to the index saw the highest yielding stocks replaced in 2024. Investors have many strategies when looking at stocks and ...

Dow Jones: The Dow Jones Industrial Average or DJIA tumbled by ... Procter & Gamble, Costo, and Eli Lilly also nosedived by 1% to 8%, contributing to the downfall. Among the gainers were Nvidia ...

A look at the best and worst performing Dow Jones Industrial Average stocks in 2024. The index completed several changes to the 30 components that will make the index and returns look different in ...